<DOC>
	<DOCNO>NCT02633371</DOCNO>
	<brief_summary>This single-center , prospective , open-label , outpatient pilot study evaluate efficacy tolerability oxybutynin gel axillary hyperhidrosis .</brief_summary>
	<brief_title>A Pilot Study Exploring Efficacy Safety Topical Oxybutynin 3 % Gel Primary Focal Hyperhidrosis Adolescents Young Adults</brief_title>
	<detailed_description>This study determine daily application topical oxybutynin 3 % gel reduce symptom primary axillary hyperhidrosis adolescent young adult . It also assess impact daily topical oxybutynin 3 % gel Health Related Quality Life ( HRQOL ) ; determine daily topical oxybutynin 3 % gel treatment effect distant , untreated site ; assess local systemic tolerability daily topical oxybutynin 3 % gel . Finally , study determine treatment effect size , one exist , order power large , placebo-controlled study future .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Eligible subject must 1225 year old meet consensus criterion primary focal hyperhidrosis : focal , visible , excessive sweating least 6 month duration without apparent cause least two follow characteristic : 1 ) Bilateral relatively symmetric , 2 ) Impairs daily activity , 3 ) Frequency least one episode per week , 4 ) Age onset less 25 year , 5 ) Positive family history , 6 ) Cessation focal sweating sleep . Eligible subject must moderate severe hyperhidrosis correlate score 3 4 HDSS . Hyperhidrosis must affect bilateral axilla ; however , patient concurrent focal hyperhidrosis affect palm , sol , face , area exclude . Subjects must willing comply study protocol . Subjects hyperhidrosis le 6 month duration hyperhidrosis secondary underlie infectious , endocrine , neurologic disorder . Treatment botulinum toxin injection axillae affected area within last 12 week OR treatment agent ( oral anticholinergic medication , topical aluminum chloride ) last 4 week . Subjects active skin inflammation infection affect axilla Subjects report history closedangle glaucoma , urinary retention , decrease gastrointestinal motility , hiatal hernia , cardiac arrhythmia , coronary artery disease , congestive health failure , hyperthyroidism , myasthenia gravis , xerostomia , renal insufficiency , hepatic impairment . Subjects hypertension define systolic blood pressure &gt; 140 diastolic blood pressure &gt; 90 1 occasion separate 1 week . Subjects following : history somnolence , confusion , hallucination OR subject take medication may cause somnolence , confusion , hallucination OR subject medical condition may predispose somnolence , confusion , hallucination . Subjects demonstrated hypersensitivity drug substance component product Subjects take drug inhibit Cytochrome P450 3A4 ( CYP3A4 ) Pregnant and/or nursing females Any disease would interfere study place undue risk way unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>